Timmer Antje, Günther Judith, Rücker Gerta, Motschall Edith, Antes Gerd, Kern Winfried V
Department of Medical Biometry and Statistics, German Cochrane Center, University Medical Center, Stefan-Meier-Str. 26, Freiburg, Germany, 79104.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD006323. doi: 10.1002/14651858.CD006323.pub2.
Pelargonium sidoides (P. sidoides), also known as Umckaloabo, is a herbal remedy thought to be effective in the treatment of acute respiratory infections (ARIs).
To assess the efficacy and safety of P. sidoides for the treatment of ARIs in children and adults.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 4) which includes the Cochrane Acute Respiratory Infections Group's Specialised Register; MEDLINE (1966 to November 2007); EMBASE (1974 to December 2007); and other electronic databases.
Randomized controlled trials (RCTs) examining the efficacy of P. sidoides preparations in ARIs compared to placebo, no treatment or any other treatment. Complete resolution of all symptoms was defined as a primary outcome.
Three review authors (AT, JG, WK) independently extracted and quality scored the data. Separate analyses were performed by age group and disease entity. Heterogeneity was examined using the I-square (I(2)) statistic. Pooled relative risks (RR) were calculated using a fixed-effect model if heterogeneity was absent (I(2) < 5%; P > 0.1), or a random-effects model in the presence of heterogeneity. If heterogeneity was substantial (I(2) > 50%; P < 0.10), a pooled effect was not calculated.
Three trials (746 patients) of efficacy in acute bronchitis in adults showed substantial heterogeneity for all relevant outcomes. and three trials (819 children) were similarly inconsistent for acute bronchitis in children. Type of preparation was a potential cause of heterogeneity (not effective in tablet form). One unpublished study in patients with sinusitis (n = 103 adults) showed significant treatment effects (complete resolution at day 21; RR 0.43, 95% CI 0.30, 0.62). One study in the common cold demonstrating efficacy after 10 days, but not five days. Four trials were excluded because of excessive risk of bias. There were no valid data for the treatment of other acute respiratory tract infections. Adverse events were more common with P. sidoides, but none were serious.
AUTHORS' CONCLUSIONS: P. sidoides may be effective in alleviating symptoms of acute rhinosinusitis and the common cold in adults, but doubt exists. It may be effective in relieving symptoms in acute bronchitis in adults and children, and sinusitis in adults. Reliable data on treatment for other ARIs were not identified.
香叶天竺葵(Pelargonium sidoides),也被称为南非香叶,是一种草药疗法,被认为对治疗急性呼吸道感染(ARIs)有效。
评估香叶天竺葵治疗儿童和成人急性呼吸道感染的疗效和安全性。
我们检索了Cochrane对照试验中央注册库(CENTRAL)(《Cochrane图书馆》2007年第4期),其中包括Cochrane急性呼吸道感染小组的专业注册库;MEDLINE(1966年至2007年11月);EMBASE(1974年至2007年12月);以及其他电子数据库。
随机对照试验(RCTs),比较香叶天竺葵制剂与安慰剂、不治疗或任何其他治疗方法在急性呼吸道感染中的疗效。所有症状完全缓解被定义为主要结局。
三位综述作者(AT、JG、WK)独立提取数据并进行质量评分。按年龄组和疾病实体分别进行分析。使用I²统计量检查异质性。如果不存在异质性(I²<5%;P>0.1),则使用固定效应模型计算合并相对风险(RR);如果存在异质性,则使用随机效应模型。如果异质性很大(I²>50%;P<0.10),则不计算合并效应。
三项关于成人急性支气管炎疗效的试验(746例患者)在所有相关结局方面显示出显著的异质性。三项关于儿童急性支气管炎的试验(819例儿童)同样不一致。制剂类型是异质性的一个潜在原因(片剂形式无效)。一项未发表的关于鼻窦炎患者的研究(n = 103例成人)显示出显著的治疗效果(第21天完全缓解;RR 0.43,95%CI 0.30,0.62)。一项关于普通感冒的研究表明10天后有疗效,但5天后没有。四项试验因偏倚风险过高而被排除。没有关于治疗其他急性呼吸道感染的有效数据。使用香叶天竺葵时不良事件更常见,但均不严重。
香叶天竺葵可能对缓解成人急性鼻-鼻窦炎和普通感冒的症状有效,但存在疑问。它可能对缓解成人和儿童急性支气管炎以及成人鼻窦炎的症状有效。未找到关于治疗其他急性呼吸道感染的可靠数据。